Introduction {#s1}
============

Hashimoto\'s thyroiditis (HT) and differentiated thyroid cancer (DTC) are the most common autoimmune and malignant thyroid diseases. Although they differ by pathophysiology, both diseases manifest on the background of genetic susceptibility and either triggering or causal environmental factors \[[@B1], [@B2]\]. These etiological characteristics become apparent in the frequent coincidence of HT with DTC, as well as in the familial clustering of the disease \[[@B3], [@B4]\].

Vitamin D (VD) deficiency represents a joint risk factor for HT \[[@B5]\] and DTC \[[@B6]\] and affects \~50% of the global population \[[@B7]\]. Thus, low levels of vitamin D have been found in HT \[[@B5]\] and DTC \[[@B8]\]. Notably, an inverse correlation of VD levels was found with the malignancy rate of thyroid nodules \[[@B6]\] as well as with thyroid antibody titers \[[@B1], [@B9]\] suggesting a causal link.

Whereas 25(OH)D~3~ is the stable inactive metabolite and used to assess the VD status in humans, 1,25(OH)~2~D~3~ is the final active form of VD, interacting with the VD receptor (VDR). By targeting various transcription factors and cell cycle proteins, the VDR mediates anti-proliferative, pro-differentiating and immune-modulating effects \[[@B10]\]. Thus, VD was reported to inhibit cell growth of thyroid cancer (TC) cells \[[@B11]\]. Moreover, VD has been shown to regulate type 1 and 17 T helper cells \[[@B12], [@B13]\], that are involved in the pathogenesis of HT \[[@B14], [@B15]\]. Appropriately, VD treatment in patients with HT has been shown to decrease levels of thyroid antibodies (Ab\'s) \[[@B16]\]. Various associations have been reported for single nucleotide polymorphisms (SNP\'s) of the VDR or VD metabolizing enzymes with both DTC \[[@B17], [@B18]\] and HT \[[@B19], [@B20]\]. Therefore VD may further impact on autoimmune and malignant thyroid diseases through genetic susceptibility. However, until now the exact molecular mechanisms of VD\'s preventive potential in HT and DTC are still unclear.

Sirtuins are histone deacetylases, which are involved in various metabolic pathways, including aging and stress response \[[@B21]\]. As NAD dependent metabolic sensors, sirtuins adjust posttranslational modification of cellular regulator proteins on energy status of the cell \[[@B22]\]. Sirtuin 1 (SIRT1) represents a subform located in the nucleus that has lately not only been shown to be regulated by the VDR, but also been interpreted as a mediator of anti-proliferative VD signals by deacetylation of forkhead box protein O3a (FOXO3a) \[[@B23]\]. SNP\'s of the FOXO3a related transcription factor forkhead box protein E1 (FOXE1) have only recently been reported as important risk factors for DTC \[[@B24]\]. Interestingly, posttranslational modification of FOXO3a by SIRT1 antagonizes the phosphatidylinositol-4,5-bisphosphate 3-pathway \[[@B25]\]. This signal cascade is activated in T-helper cells (Thc) upon T cell receptor activation \[[@B26]\] and has been found to be oncogenic in thyroid carcinoma \[[@B27]\]. This suggests a potential key role of VD-SIRT1-FOXO3a signaling in immune regulation and DTC.

To the best of our knowledge, the VD-SIRT1-FOXO3a interaction has never been investigated in relation to autoimmune and malignant thyroid diseases. In this study, we aimed to examine common *FOXO3a* SNP\'s for association with autoimmune or malignant thyroid diseases. Moreover we questioned the SIRT1-dependency of anti-proliferative VD effects on immune cells and malignant thyroid cells as an indication of VD-SIRT1-FOXO3a interaction constituting a molecular pathway of protective VD effects.

Materials and methods {#s2}
=====================

Subjects
--------

In total 257 patients (172 females and 85 males, median age: 55 years) with pathologically confirmed diagnosis of DTC (208 of papillary differentiation and 49 of follicular differentiation) as well as 139 patients with HT (116 females and 23 males, median age: 40 years) were recruited from the Department of Medicine 1 and the Department of Nuclear Medicine at the University Hospital Frankfurt am Main, Germany as well as from the Department of Surgery at the Bürgerhospital Frankfurt am Main, Germany. Furthermore 463 healthy controls (HC, 228 females and 235 males, median age: 37 years) were volunteer blood donors.

The study protocol was approved by the Ethics Committee of the University Hospital Frankfurt am Main. Informed and written consent was obtained from all participants.

Methods {#s3}
=======

Measurement of vitamin D metabolites and thyroid antibodies
-----------------------------------------------------------

The 25(OH)D~3~ and 1,25(OH)~2~D~3~ plasma levels were measured by radioimmunoassay (DiaSorin, Stillwater, Minnesota, USA and IDS, Frankfurt am Main, Germany) in blood samples of DTC, HT, and HC. The expected normal range (95% reference interval) in healthy adults using this method is 9.0--37.6 ng/ml for 25(OH)D~3~ and 18.06--70.56 pg/ml for 1,25 (OH)~2~D~3~ level with a reported coefficient of variance of \< 20% and \< 11%, respectively. An enzyme-linked immunosorbent assay (Phadia, Freiburg, Germany) was used to determine serum levels of thyroglobulin (Tg)- and thyroperoxidase (TPO)- Ab\'s in patients with HT (*n* = 91).

Single nucleotide polymorphism analysis
---------------------------------------

The *FOXO3a* gene is located on chromosome 6 at the gene locus q21 (6q21). Three single nucleotide polymorphisms (SNP\'s) within *FOXO3a* gene were studied in DTC, HT and HC. The SNPs rs4946936 and rs4945816 are located at the 3′ untranslated (UTR) region of *FOXO3a*. The third SNP rs9400239 is located at the 5′ end of *FOXO3a*.

Genomic DNA from all blood samples was isolated by Miller and Dakes salting out procedure and subsequently amplified by polymerase chain reaction. The SNP\'s within the *FOXO3a* gene rs4946936 and rs4945816 (both specifically designed by Applied Biosystems) and rs9400239 (Assay-ID: C\_\_11904122_10, Applied Biosystem) were analyzed using Taqman assays in an ABI 7300 system with conditions, recommended by the manufacturer. Random samples of the *FOXO3a* rs4946936 and *FOXO3a 9400239* were analyzed twice in order to confirm the accuracy of the applied method. The results revealed a concordance rate of 100%.

Isolation of T-helper cells
---------------------------

Ten HC, consisting of 5 men and 5 women (median age: 26 years) were recruited for analysis of physiological VD--SIRT1-FOXO3a pathway in immune cells. Therefore, Thc were isolated from peripheral blood mononuclear cells of the subjects by using the CD4 T cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). During cell cultivation in basic cell medium, all cells were supplemented with the T cell mitogen phytohemagglutinin (PHA, Sigma-Aldrich) in concentrations of 50 μg/ml.

Cell line preparation
---------------------

Human papillary thyroid cancer cell line BCPAP ([RRID:CVCL_0153](https://scicrunch.org/resolver/RRID:CVCL_0153)) was obtained from Leibniz Institute DSMZ, German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). This cell line was authenticated by DSMZ using multiplex PCR of minisatellite markers. The cells were processed immediately upon receipt and cells of passage four were used for five repetitions of the following cell culture approaches.

Cell cultivation
----------------

All cells were cultivated in RPMI-1640, that was supplemented with 10% FCS, 1% penicillin-streptomycin and 25 mM Hepes (basic cell medium) and were seeded out in volumes of 5 × 10^5^ cells/ml in 6 well plates, in case of BCPAP cells (Sigma-Aldrich, munich, Germany, growth area: 9.5 cm^2^) or 24 well plates in case of Thc (Sigma-Aldrich, growth area: 1.9 cm^2^). Furthermore, either 10 nM 1,25(OH)~2~D~3~ or 2.4 μM of the SIRT1 inhibitor Ex-527 \[that have been reported to abolish SIRT1 activity by virtually 100%, respectively \[[@B28]\]\] or the combination of 1,25(OH)~2~D~3~ and Ex-527 were added.

The cells were incubated at 37°C. Forty-eight and ninety-six hours after isolation, cells were detached from the plates, requiring trypsinization in case of thyroid cells. Finally all cells were counted using hemocytometer.

Gene expression analysis
------------------------

A total of 18 ng RNA was extracted from BCPAP cells and Thc for reverse transcription into cDNA (Affinity Script QPCR, Agilent Technologies, Waldbronn, Germany). Quality control of RNA-integrity was performed previous to reverse transcription, using 2100 Bioanalyzer (Agilent Technologies). Subsequently, gene expression of *FOXO3a* (Hs00921424_m1) and the endogenous control 18s (Hs99999901_s1) were measured by Taqman assay (Applied Biosystems). Gene expression were compared as relative levels of cycle threshold (CT) normalized to the endogenous controls, calculated by 2^−\[CTtarget(t)−CT18s(t)\]^ × 10^6^.

Statistical analysis
--------------------

The statistical analyses were performed using BiAS statistic software package 10.0 (Epsilon, Weinheim, Germany). Differences in genotype and allele distributions between all groups were evaluated by chi-square test. The odds ratio (OR) and its 95% confidence interval (CI) were estimated by unconditional logistic regression. CT-values, levels of thyroid Ab\'s, and cell proliferation were analyzed by non-parametric tests (Willcoxon-Mann-Whitney-U-test, Kruskall-Wallis-test and Wilcoxon matched pairs test).

In case of multiple comparisons, *p* values were corrected by multiplying them with the number of comparisons tested (Bonferroni correction). *P*-values (p or p~c~, respectively) \< 0.05 were considered significant, *p*-values (p or p~c~, respectively) \< 0.10 were considered as a trend.

Results {#s4}
=======

*FOXO3a* single nucleotide polymorphisms in patients with differentiated thyroid carcinoma
------------------------------------------------------------------------------------------

DTC and HC were genotyped for the SNP\'s *FOXO3a* rs4946936, rs4945816, and rs9400239. The genotypes of all groups were in Hardy Weinberg equilibrium (*p* \> 0.05).

The genotype analyses of all three SNP\'s did not show any differences between DTC and HC (Supplemental Table [1](#SM1){ref-type="supplementary-material"}). However allele analysis of *FOXO3a* rs4946936 revealed a tendency of a higher frequency of allele "C" in DTC in comparison to HC ("C": DTC vs. HC = 72.4% vs. 66.7%, OR: 1.28\[CI 0.99--1.66\], p~c~ = 0.08, Supplemental Table [1](#SM1){ref-type="supplementary-material"}). Allele and genotype distributions did not show association with markers of malignancy in DTC (tumor grade, TNM classification). Moreover, no correlation was found between genotypes of all investigated SNP\'s and VD status (DTC: Median level: 25(OH)D~3~ = 17.0 ng/ml and 1,25(OH)~2~D~3~ = 36.0 pg/ml; HC: 25(OH)D~3~ = 19.95 ng/ml and 1,25(OH)~2~D~3~ = 52.7 pg/ml, consistent within all genotypes, data not shown).

*FOXO3a* single nucleotide polymorphisms in patients with hashimoto thyroiditis
-------------------------------------------------------------------------------

*FOXO3a* rs4946936, rs4945816, and rs9400239 were analyzed in 139 HT. Genotype analysis showed elevated frequency of "TT" in rs9400239 and "CC" in rs4945816 in patients with HT (*FOXO3a* rs9400239: "TT": HT vs. HC = 16.5 vs. 9.3%, p~c~ = 0.06; *FOXO3a* rs4945816: "CC": HT vs. HC = 15.1 vs. 8.8%, p~c~ = 0.06, Table [1](#T1){ref-type="table"}). Moreover, HT carried allele T in rs9400239 and allele C in rs4945816 significantly more often than HC (*FOXO3a* rs9400239: "T": HT vs. HC = 39.9 vs. 31.4%, OR: 1.45 \[CI 1.10--1.91\], p~c~ = 0.02; *FOXO3a* rs4945816: "C": HT vs. HC = 39.6 vs. 30.5%, OR: 1.5 \[CI 1.12--2.00\], p~c~ = 0.01). These associations were especially strong in males (*FOXO3a* rs9400239: "T": HT♂ vs. HC♂ = 52.2 vs. 30.9%, OR: 2.05 \[CI 1.12--3.78\], p~c~ = 0.04, *FOXO3a* rs4945816: "C": HT♂ vs. HC♂ = 47.8 vs. 29.9%, OR: 2.15 \[CI 1.15--4.04\], p~c~ = 0.04, Table [1](#T1){ref-type="table"}). We also analyzed the Tg- and TPO Ab\'s levels in relation to *FOXO3a* rs9400239 and rs4945816 genotypes. However we could not find significant differences (data not shown).

###### 

Distribution of *FOXO3a* single nucleotide polymorphisms in Hashimoto thyroiditis and healthy controls.

  **Genotype/** ***n*** **(frequency)**   **Allele/** ***n*** **(frequency)**                                                                                                                                                        
  --------------------------------------- ------------------------------------- ------------- ------------- ------------- ----------- ---------- ------------- ------------- --------------------- --------------------- ----------- ----------
  **FOXO3a rs4946936**                                                                                                                                                                                                               
  HC                                      362                                   156 (43.1%)   171 (47.2%)   35 (9.7%)                            483 (66.7%)   241 (33.3%)                                                           
  HT                                      139                                   50 (36.0%)    70 (50.4%)    19 (13.7%)    0.23        0.69       170 (61.2%)   108 (38.8%)   0.79 \[0.59--1.05\]   1.27 \[0.96--1.7\]    0.11        0.22
  HC♀                                     208                                   89 (42.8%)    99 (47.6%)    20 (9.6%)                            277 (66.6%)   139 (33.4%)                                                           
  HT♀                                     116                                   43 (37.1%)    59 (50.9%)    14 (12.1%)    0.55        1.65       145 (62.5%)   87 (37.5%)    0.84 \[0.60--1.17\]   1.20 \[0.86--1.67\]   0.34        0.68
  HC♂                                     154                                   67 (43.5%)    72 (46.8%)    15 (9.7%)                            206 (66.9%)   102 (33.1%)                                                           
  HT♂                                     23                                    7 (30.4%)     11 (47.8%)    5 (21.7%)     0.19        0.57       21 (45.7%)    25 (54.3%)    0.59 \[0.31--1.10\]   1.74 \[0.91--3.18\]   0.13        0.26
  **FOXO3a rs4945816**                                                                                                                                                                                                               
  HC                                      353                                   31 (8.8%)     153 (43.3%)   169 (47.9%)                          215 (30.5%)   491 (69.5%)                                                           
  HT                                      139                                   21 (15.1%)    68 (48.9%)    50 (36.0%)    **0.02**    **0.06**   110 (39.6%)   168 (60.4%)   1.50 \[1.12--2.00\]   0.67 \[0.50--0.89\]   **0.007**   **0.01**
  HC♀                                     204                                   17 (8.3%)     92 (45.1%)    95 (46.6%)                           126 (30.9%)   282 (69.1%)                                                           
  HT♀                                     116                                   14 (12.1%)    60 (51.7%)    42 (36.2%)    0.17        0.51       88 (37.9%)    144 (62.1%)   1.37 \[0.98--1.92\]   0.73 \[0.52--1.03\]   0.08        0.16
  HC♂                                     146                                   14 (9.4%)     61 (40.9%)    71 (49.7%)                           89 (29.9%)    209 (70.1%)                                                           
  HT♂                                     23                                    7 (30.4%)     8 (34.8%)     8 (34.8%)     **0.01**    **0.04**   22 (47.8%)    24 (52.2%)    2.15 \[1.15--4.04\]   0.46 \[0.25--0.87\]   **0.02**    **0.04**
  **FOXO3a rs9400239**                                                                                                                                                                                                               
  HC                                      463                                   215 (46.4%)   205 (44.3%)   43 (9.3%)                            635 (68.6%)   291 (31.4%)                                                           
  HT                                      139                                   51 (36.7%)    65 (46.8%)    23 (16.5%)    **0.02**    **0.06**   167 (60.1%)   111 (39.9%)   0.69 \[0.52--0.91\]   1.45 \[1.10--1.91\]   **0.01**    **0.02**
  HC♀                                     228                                   104 (45.6%)   102 (44.7%)   22 (9.7%)                            310 (68.9%)   146 (32.9%)                                                           
  HT♀                                     116                                   43 (37.1%)    57 (49.1%)    16 (13.8%)    0.24        0.72       143 (61.6%)   89 (38.4%)    0.76 \[0.54--1.05\]   1.32 \[0.95--1.84\]   0.11        0.22
  HC♂                                     235                                   111 (47.2%)   103 (43.8%)   21 (8.9%)                            325 (69.1%)   145 (30.9%)                                                           
  HT♂                                     23                                    7 (30.4%)     8 (34.8%)     8 (34.8%)     **0.006**   **0.01**   22 (47.8%)    24 (52.2%)    0.49 \[0.26--0.90\]   2.05 \[1.12--3.78\]   **0.02**    **0.04**

*The single nucleotide polymorphisms FOXO3a rs4946936, rs4945816 and rs9400239 were genotyped in patients with HT (n = 139) and HC (n = 463). HT showed higher frequency of minor allele "T" in rs9400239 and "C" in rs4945816 in comparison to HC. The differences were especially strong in male patients leading to an elevated risk of 2.05 in male carriers of rs9400239T and of 2.15 in male carriers of rs4945816C. Significant asociations are displayed in bold*.

The genotypes and alleles of *FOXO3a* rs4946936 did not differ between HT and HC.

No correlation was found between genotypes of all investigated SNP\'s and VD status (HT: Median level: 25(OH)D~3~ = 18.35 ng/ml and 1,25(OH)~2~D~3~ = 51.0 pg/ml, consistent within all genotypes, data not shown).

SIRT1-dependent VD effects on cell proliferation in T-helper cells
------------------------------------------------------------------

Since FOXO3a was reported as a target of the VD cascade by mediation of SIRT1, the effects of VD on cell proliferation were analyzed in relation to SIRT1 activity. Hereby, Thc of HC served as a model of physiologic VD-SIRT1-FOXO3a interaction.

We observed a significant cell suppressive effect of 1,25(OH)~2~D~3~ on Thc after 48 and 96 h (Median cell count(48 h): 1,25(OH)~2~D~3~ vs. Co = 2.48 × 10^5^ vs. 4.16 × 10^5^ cells/ml, *p* = 0.002, Figure [1A](#F1){ref-type="fig"}, 96 h: 1,25(OH)~2~D~3~ vs. Co = 6.86 × 10^5^ vs. 1.15 × 10^6^, *p* = 0.02 Figure [1B](#F1){ref-type="fig"}). Interestingly the cell suppressive effect of VD was blocked in cells that were additionally supplemented with the SIRT1 inhibitor Ex-527 after 48 h (Ex-527+1,25(OH)~2~D~3~ vs. 1,25(OH)~2~D~3~ = 2.81 × 10^5^ vs. 2.48 × 10^5^ cells/ml, *p* = 0.0059, Figure [1A](#F1){ref-type="fig"}).

![Effect of vitamin D supplementation and SIRT1 inhibition on proliferation on T-helper cells. Thc of 10 HC were supplemented with the following reagents in cell counts of 1 x 10^5^ cells/ml: 10 nM 1,25(OH)~2~D~3~ or 2.4 μM Ex-527, or 10 nM 1,25(OH)~2~D~3~+2.4 μM Ex-527. After 48 h **(A)** and 96 h **(B)** of cell cultivation, cell proliferation was measured by hemocytometer. Figure shows the mean value (bar level), the median (bold line), the standard deviation and maximum level of the measured cell counts in the corresponding groups of cell approaches.](fendo-09-00527-g0001){#F1}

Supplementation with Ex-527 alone did not affect cell count after 48 and 96 h of cell cultivation (Figures [1A,B](#F1){ref-type="fig"}).

SIRT1-dependent VD effects on cell proliferation in cell line BCPAP
-------------------------------------------------------------------

Based on the insights of physiological VD/SIRT1/FOXO3a interplay in immune cells, a similar experimental setup was carried out in papillary thyroid cancer cells. None of the reagents affected BCPAP cell proliferation within 48 h of cultivation (1,25(OH)~2~D~3~ vs. Co; 1,25(OH)~2~D~3~+Ex-527 vs. 1,25(OH)~2~D~3~, Ex-527 vs. Co, p~each~\>0.05, Figure [2A](#F2){ref-type="fig"}). However, as seen for Thc, we observed a significant inhibitory effect of 1,25(OH)~2~D~3~ on cell proliferation after 96 h (1,25(OH)~2~D~3~ vs. Co = 5.6 × 10^5^ vs. 1.2 × 10^6^ cells/ml, *p* = 8 × 10^−3^). Moreover, once again addition of SIRT1 inhibitor Ex-527 to 1,25(OH)~2~D~3~ treated cells reduced the anti-proliferative effect of 1,25(OH)~2~D~3~ (1,25(OH)~2~D~3~+Ex-527 vs. 1,25(OH)~2~D~3~ = 9.5 × 10^5^ vs. 5.6 × 10^5^ cells/ml, *p* = 0.04, Figure [2B](#F2){ref-type="fig"}). SIRT1 inhibition by Ex-527 alone did not affect cell proliferation of BCPAP after 48 and 96 h of cell cultivation (Figures [2A,B](#F2){ref-type="fig"}).

![Effect of vitamin D supplementation and SIRT1 inhibition on proliferation on papillary thyroid cancer cells. Papillary thyroid cancer cells of cell line BCPAP were supplemented with the following reagents in cell counts of 1 × 10^5^ cells/ml: 10 nM 1,25(OH)~2~D~3~ or 2.4 μM Ex-527, or 10 nM 1,25(OH)~2~D~3~+2.4 μM Ex-527. After 48 h **(A)** and 96 h **(B)** of cell cultivation, cell proliferation was measured by hemocytometer. Figure shows the mean value (bar level), the median (bold line), the standard deviation and maximum level of the measured cell counts in the corresponding groups of cell approaches.](fendo-09-00527-g0002){#F2}

SIRT1-dependent VD effects on *FOXO3a* gene expression in T- helper cells and cell line BCPAP
---------------------------------------------------------------------------------------------

Thc and BCPAP were further analyzed for SIRT1 dependent VD effects on *FOXO3a* gene expression level. Interestingly, VD supplemented Thc showed significant increase in *FOXO3a* gene expression after 48h (1,25(OH)~2~D~3~ vs. Co: 20.52 vs. 13.28 2^−(CT\ FOXO3a−CT\ 18s)^ × 10^6^, *p* = 0.05, Table [2](#T2){ref-type="table"}). Remarkably, Thc cultivated with VD+Ex-527 did not differ in *FOXO3a* gene expression levels from Thc supplemented with 1,25(OH)~2~D~3~ alone (1,25(OH)~2~D~3~ vs. 1,25(OH)~2~D~3~+Ex-527: 20.52 vs. 21.66 2^−(CTFOXO3a−CT\ 18s)^x10^6^, *p* \> 0.05, Table [2](#T2){ref-type="table"}). After 96 h of cultivation no effects were seen on *FOXO3a* gene expression for neither VD supplementation, nor the combination of VD and Ex-527 (data not shown).

###### 

Effect of vitamin D stimulation and SIRT1 inhibition on *FOXO3a* gene expression in T-helper cells and BCPAP cells.

  **48 h**                 **T-helper cells**   **BCPAP cells**           
  ------------------------ -------------------- ----------------- ------- ------
  Co                       13.28                                  98.47   
  1,25(OH)~2~D~3~          20.52                **0.05**          99.84   0.81
  1,25(OH)~2~D~3~          20.52                                  99.84   
  Ex-527+1,25(OH)~2~D~3~   21.66                0.73              76.19   0.13

*PHA-stimulated T-helper cells and B-CPAP cells were cultivated in 5 × 10^5^ cell approaches with 1,25(OH)~2~D~3~ or SIRT1 inhibitor Ex-527 or 1,25(OH)~2~D~3~ + Ex-527. After 48h of cultivation FOXO3a gene expression was measured by real time PCR and compared to cell approaches without any additions (Co). 1,25(OH)~2~D~3~ increased FOXO3a gene expression significantly after 48 h of supplementation. Significant asociations are displayed in bold*.

In contrast to Thc, VD supplementation did not affect *FOXO3a* gene expression in BCPAP. Also the combination of VD and SIRT1 inhibitor did not alter *FOXO3a* gene expression in papillary TC cells (Table [2](#T2){ref-type="table"}).

Discussion {#s5}
==========

Protective effects of vitamin D have been reported in several autoimmune \[[@B29]\] and malignant diseases \[[@B30]\], though little is known about the underlying molecular mechanisms.

In thyroid diseases, out of the VD pathway SNP\'s in the VDR are the best-studied genetic associations with HT and DTC. Four polymorphisms detected by restriction enzymes FokI, BsmI, ApaI, and TaqI have been investigated extensively in relation to thyroid diseases. Changes of the predicted VDR protein sequence at the FokI and ApaI sites have been associated with DTC \[[@B18]\] whereas FokI, BsmI, and TaqI have been related to autoimmune thyroid diseases \[[@B31]--[@B33]\].

New aspects of VD\'s mode of action affect SIRT1, a histone deacetylase implicated in cancer formation \[[@B34], [@B35]\] and autoimmune mechanisms \[[@B36]\]. Enzymatic activation of SIRT1 by the VDR mediates deacetylation and hereby reactivation of the transcription factor FOXO3a \[[@B23]\]. Interestingly, this forkheadbox protein is also found to be inhibited in DTC \[[@B37]\] and Thc upon stimulation \[[@B26]\]. This concurrence suggests that FOXO3a could be a key mediator of VD\'s anti-proliferative and immune regulatory effects, also affecting the pathogenesis of DTC and HT. Since genetic variations of other members of the forkhead box protein family have already been identified as important risk factors for thyroid diseases \[[@B24]\], we questioned the association of *FOXO3a* SNP\'s with DTC and HT. Thus, *FOXO3a* rs4946936T has already been reported to be associated with vitiligo, an autoimmune disease that often occurs together with HT \[[@B38]\]. In fact, *FOXO3a* rs9400239T and rs4945816C were associated with HT in our study group. To our knowledge, this is the first report of *FOXO3a* SNP\'s showing associations with autoimmune thyroid disease. Due to the limited number of patients, these observations need to be confirmed in a larger cohort. Since, rs9400239T or rs4945816C did not correlate with the Tg- or TPO-Ab level in HT, the underlying pathomechanism may not directly impact on antibody related immunological mechanisms.

Consistent with recent analyses of *FOXO3a* SNP\'s in cancers of other origin \[[@B39]\], we only found tendencies toward a higher frequency of *FOXO3a* rs4946936C in DTC. Future studies with more probands should elucidate the relevance of the observed distributions.

Despite its function as a target of the VD cascade, the association of *FOXO3a* SNP\'s with HT did not correlate with the VD status of the patients. In line with this observation, the *FOXO3a* gene itself does not harbor any VDRE\'s and FOXO3a transcriptional control is thought to occur via a VDRE in a neighboring gene \[[@B40]\].

A molecular explanation for the functional relevance of those non-coding SNP\'s could be an interaction with micro RNA\'s \[[@B41]\] affecting *FOXO3a* mRNA expression levels \[[@B42]\]. Consistent with this observation, *FOXO3a* gene expression has been reported to be dysregulated in DTC \[[@B37]\].

Next we turned to the *in vitro* situation and questioned the dependency of protective VD effects on SIRT1-FOXO3a axis. In fact, our investigations indicate anti-proliferative effects of 1,25(OH)~2~D~3~ to depend on SIRT1 activity in Thc and cancer cells. Thus, the presence of the SIRT1 inhibitor Ex-527 in concentrations, known to abolish SIRT1 activity by virtually 100% \[[@B28]\], reduced the cell suppressive effect of 1,25(OH)~2~D~3~ on BCPAP and Thc. Our results therefore indicate SIRT1 to be a crucial component of VD\'s anti-proliferative signals in thyroid cancer cells and immune cells. Appropriately, those cell cycle regulative and pro-apoptotic genes that have been attributed as molecular mediators of VD\'s protective effects, such as Bim or GADD45 \[[@B43], [@B44]\], are also induced by SIRT1 activated FOXO3a \[[@B45], [@B46]\]. In line with our investigations in DTC and immune cells, Sabir et al. only recently reported attenuation of VD signaling by Ex-527 in two different human non-thyroid cell lines \[[@B47]\]. Furthermore An et al. linked VD signaling with enhanced cell cycle control by FOXO3a \[[@B23]\].

Our analyses further revealed a SIRT1 independent interaction of FOXO3a and the VD pathway in Thc. Thus, we observed a stimulative effect of 1,25(OH)~2~D~3~ on *FOXO3a* transcription in Thc, that wasn\'t affectable by SIRT1 inhibition. In contrast, this effect was not seen in papillary thyroid cancer cells of cell line BCPAP. Considering recent reports of *FOXO3a* gene expression being dysregulated in DTC \[[@B37]\], separation of FOXO3a transcriptional control from VD signaling should be focused in future studies as a potential oncogenic pathomechanism.

The impact of enzymatic SIRT1 activation or inhibition on thyroid cancer cell growth *in vitro* is poorly examined. Thus, while Shih et al. analyzed the effects of unspecific SIRT1 activator Resveratrol on proliferation and apoptosis of thyroid cancer cell lines \[[@B9]\], this is the first study to investigate the effect of SIRT1 inhibitor Ex-527. Whilst, Resveratrol induced apoptosis in thyroid cancer cells \[[@B9]\] we did not find effects of SIRT1 inhibition on cell proliferation of Thc and BCPAP cells.

Conclusion {#s6}
==========

In conclusion, this is the first study that reports FOXO3a to be associated with autoimmune thyroid diseases. Thus, we could identify two SNP\'s that may constitute genetic risk factors for HT. Moreover, VD-SIRT1 interaction could be confirmed in DTC cells and immune cells, suggesting SIRT1 to be a crucial mediator of immune regulatory and anti-proliferative action and indicating SIRT-FOXO3a as downstream targets of VD effects. So far VD is not a component of DTC therapy or treatment of autoimmune thyroid diseases. A combination of VD with SIRT1 activators, such as resveratrol or SRT1720 \[[@B48]\], could be a promising approach for upcoming anti-proliferative therapies.
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Ab

:   Antibody

CI

:   confidence interval

Co

:   control

DMSO

:   dimethylsulfoxide

DTC

:   differentiated thyroid cancer

FCS

:   fetal calf serum

GAPDH

:   Glycerinaldehyd-3-phosphat dehydrogenase

h

:   hours

HC

:   healthy controls

LD

:   linkage disequilibrium

OR

:   odds ratio

pc

:   corrected p-values

PHA

:   phytohemagglutinin

RT-PCR

:   real time polymerase chain reaction

SIRT1

:   Sirtuin1

SNP

:   single nucleotide polymorphism

Thc

:   T-helper cell

Tg

:   thyroglobulin

TPO

:   thyroperoxidase

UTR

:   untranslated

VD

:   vitamin D

VDR

:   vitamin D Receptor.
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